Hemant Surgical Industries Ltd

AGM Details

• AGM held on 29-09-2026 from 12:30 p.m. to 1:15 p.m. via VC/OAVM; record date 22-09-2026.

Key Resolutions

• Adopt audited standalone and consolidated financial statements for FY2026.
• Re-appoint Hemant Praful Shah as Director by rotation.
• Ratify remuneration of Cost Auditors.

Voting Results

• Resolution 1 passed; 82,92,000 votes for, 0 against.
• Resolution 2 passed; 82,92,000 votes for, 0 against.
• Resolution 3 passed; 82,92,000 votes for, 0 against (99.92%).

Director Changes

• Hemant Praful Shah re-appointed as Director by rotation.

Auditors

• Remuneration of Cost Auditors ratified.

AGM Details

• Date/time: 29 Sep 2026, 12:30 p.m., via VC/OAVM.
• Cut-off for voting: 22 Sep 2026.
• Remote e-voting window: 26–28 Sep 2026.
• Quorum: 16 shareholders via VC/OAVM.
• Meeting concluded at 1:15 p.m.
• Platform: NSDL; Scrutinizer: Nikita Kedia.

Resolutions

• Ordinary: Adoption of Audited standalone and consolidated financial statements for FY ended 31 Mar 2026.
• Ordinary: Re-appointment of Hemant Praful Shah as Director by rotation.
• Ordinary: Ratification of remuneration of Cost Auditors.

Voting Status

• Voting results not disclosed in filing; to be declared within two working days.

Dividend

• No dividend proposed or declared.

Director Changes

• Director re-appointment by rotation: Hemant Praful Shah.

Auditor Actions

• Remuneration ratification of Cost Auditors approved.

Related Party Transactions

• No material related party transactions disclosed.

Hemant Surgical Industries Ltd – Closure of Trading Window from Oct 01, 2026 in connection with Unaudited Financial Results for the half year ending Sep 30, 2026; The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchange.

Key Decisions

• Approved Directors' Report and MD&A for FY ended 31 March 2026.
• AGM fixed on 29 September 2026 at 12:30 PM via VC/OAVM.

Dematerialisation status

• Not applicable; entire holding in demat form, no rematerialisation requests.
• No dematerialisation/rematerialisation requests were received during the period.

Acquisition

• Hemant Surgical acquired 66.66% of Lifesenz Cancer Research Labs for Rs. 19.98 crore.
• Lifesenz became a subsidiary effective June 1, 2026.

Business focus

• Lifesenz operates in precision oncology and personalized cancer treatment solutions.
• It uses ex-vivo chemo-sensitivity analysis with patient-derived 3D cancer cell models.

Strategic impact

• The acquisition expands Hemant Surgical beyond traditional healthcare distribution into advanced diagnostics.
• Management expects stronger hospital and clinician relationships and future precision medicine expansion.

Financial outlook

• Management said Lifesenz is in a growth phase and may take time to break even.
• The deal was completed on an arm's length basis.

Operational plans

• Hemant Surgical plans to scale operations, expand patient adoption, and increase commercialization opportunities.